Lee's picks up China rights to Dilafor's tafoxiparin
This article was originally published in Scrip
Executive Summary
Lee's Pharmaceutical Holdings has added to its list of licensing partners through an agreement with the private Swedish drug development firm Dilafor for Chinese rights to tafoxiparin.